A phase II trial of erlotinib as front-line treatment in clinically selected patients with nonsmall-cell lung cancer

Clinical Lung Cancer

Volumn 13, Issue 2, 2012, Pages 129-135

  Pallis, Athanasios G ^a   Voutsina, Alexandra ^a   Kentepozidis, Nikolaos ^a   Giassas, Stylianos ^a   Papakotoulas, Pavlos ^a   Agelaki, Sofia ^a   Tryfonidis, Kostas ^a   Kotsakis, Athanasios ^a   Vamvakas, Lambros ^a   Vardakis, Nikolaos ^a   Georgoulias, Vassilis ^a  

^a Hellenic Oncology Research Group HORG   (Greece)

Author keywords

EGFR; Erlotinib; First line; KRAS; Mutations; NSCLC

Indexed keywords

EPIDERMAL GROWTH FACTOR RECEPTOR; ERLOTINIB;

ADULT; AGED; ARTICLE; CANCER CHEMOTHERAPY; CANCER SURVIVAL; CAUCASIAN; CLINICAL ARTICLE; CONTROLLED STUDY; DIARRHEA; DRUG EFFICACY; DRUG ERUPTION; FEMALE; GENE MUTATION; HUMAN; HUMAN CELL; HUMAN TISSUE; INTENTION TO TREAT ANALYSIS; LUNG NON SMALL CELL CANCER; MALE; OUTCOME ASSESSMENT; OVERALL RESPONSE RATE; OVERALL SURVIVAL; PHASE 2 CLINICAL TRIAL; POST TREATMENT SURVIVAL; PROGRESSION FREE SURVIVAL; SURVIVAL RATE; TREATMENT RESPONSE; WILD TYPE;

ADENOCARCINOMA; ADENOCARCINOMA, BRONCHIOLO-ALVEOLAR; ADULT; AGED; AGED, 80 AND OVER; CARCINOMA, NON-SMALL-CELL LUNG; FEMALE; FOLLOW-UP STUDIES; HUMANS; LUNG NEOPLASMS; MALE; MIDDLE AGED; MUTATION; NEOPLASM STAGING; PROGNOSIS; PROTEIN KINASE INHIBITORS; QUINAZOLINES; RECEPTOR, EPIDERMAL GROWTH FACTOR; SURVIVAL RATE;

EID: 84857381002     PISSN: 15257304     EISSN: 19380690     Source Type: Journal    
DOI: 10.1016/j.cllc.2011.08.004     Document Type: Article

References (42)

1. F.A. Shepherd, P.J. Rodrigues, T. Ciuleanu Erlotinib in previously treated nonsmall-cell lung cancer N Engl J Med 353 2005 123 132 (Pubitemid 41058344)
2. E.S. Kim, V. Hirsh, T. Mok Gefitinib versus docetaxel in previously treated nonsmall-cell lung cancer (INTEREST): a randomised phase III trial Lancet 372 2008 1809 1818
3. R.S. Herbst, G. Giaccone, J.H. Schiller Gefitinib in combination with paclitaxel and carboplatin in advanced nonsmall-cell lung cancer: a phase III trialINTACT 2 J Clin Oncol 22 2004 785 794 (Pubitemid 41103589)
4. G. Giaccone, R.S. Herbst, C. Manegold Gefitinib in combination with gemcitabine and cisplatin in advanced nonsmall-cell lung cancer: a phase III trialINTACT 1 J Clin Oncol 22 2004 777 784 (Pubitemid 41103588)
5. U. Gatzemeier, A. Pluzanska, A. Szczesna Phase III study of erlotinib in combination with cisplatin and gemcitabine in advanced nonsmall-cell lung cancer: the Tarceva Lung Cancer Investigation Trial J Clin Oncol 25 2007 1545 1552 (Pubitemid 46733081)
6. R.S. Herbst, D. Prager, R. Hermann TRIBUTE: a phase III trial of erlotinib hydrochloride (OSI-774) combined with carboplatin and paclitaxel chemotherapy in advanced non-small-cell lung cancer J Clin Oncol 23 2005 5892 5899
7. C.H. Yang, J.Y. Shih, K.C. Chen Survival outcome and predictors of gefitinib antitumor activity in East Asian chemonaive patients with advanced nonsmall cell lung cancer Cancer 107 2006 1873 1882
8. V.A. Miller, M.G. Kris, N. Shah Bronchioloalveolar pathologic subtype and smoking history predict sensitivity to gefitinib in advanced nonsmall-cell lung cancer J Clin Oncol 22 2004 1103 1109 (Pubitemid 41095044)
9. G. Giaccone, J.A. Rodriguez EGFR inhibitors: what have we learned from the treatment of lung cancer? Nat Clin Pract Oncol 2 2005 554 561 (Pubitemid 41721815)
10. T.J. Lynch, D.W. Bell, R. Sordella Activating mutations in the epidermal growth factor receptor underlying responsiveness of nonsmall-cell lung cancer to gefitinib N Engl J Med 350 2004 2129 2139 (Pubitemid 38637993)
11. J.G. Paez, P.A. Janne, J.C. Lee EGFR mutations in lung cancer: correlation with clinical response to gefitinib therapy Science 304 2004 1497 1500 (Pubitemid 38720929)
12. W. Pao, V. Miller, M. Zakowski EGF receptor gene mutations are common in lung cancers from "never smokers" and are associated with sensitivity of tumors to gefitinib and erlotinib Proc Natl Acad Sci U S A 101 2004 13306 13311 (Pubitemid 39209661)
13. D.H. Lee, J.Y. Han, H.G. Lee Gefitinib as a first-line therapy of advanced or metastatic adenocarcinoma of the lung in never-smokers Clin Cancer Res 11 2005 3032 3037
14. W. Akerley, K.M. Boucher, J.S. Bentz A phase II study of erlotinib as initial treatment for patients with stage IIIB-IV non-small cell lung cancer J Thorac Oncol 4 2009 214 219
15. D.M. Jackman, B.Y. Yeap, N.I. Lindeman Phase II clinical trial of chemotherapy-naive patients > or = 70 years of age treated with erlotinib for advanced nonsmall-cell lung cancer J Clin Oncol 25 2007 760 766 (Pubitemid 350002874)
16. S. Niho, K. Kubota, K. Goto First-line single agent treatment with gefitinib in patients with advanced non-small-cell lung cancer: a phase II study J Clin Oncol 24 2006 64 69 (Pubitemid 46630495)
17. R. Suzuki, Y. Hasegawa, K. Baba A phase II study of single-agent gefitinib as first-line therapy in patients with stage IV nonsmall-cell lung cancer Br J Cancer 94 2006 1599 1603 (Pubitemid 43924920)
18. G. Giaccone, R.M. Gallegos, C.T. Le Erlotinib for frontline treatment of advanced non-small cell lung cancer: a phase II study Clin Cancer Res 12 2006 6049 6055 (Pubitemid 44703768)
19. F. Cappuzzo, C. Ligorio, P.A. Janne Prospective study of gefitinib in epidermal growth factor receptor fluorescence in situ hybridizationpositive/ phospho-Akt-positive or never smoker patients with advanced nonsmall-cell lung cancer: the ONCOBELL trial J Clin Oncol 25 2007 2248 2255 (Pubitemid 46954651)
20. P. Therasse, S.G. Arbuck, E.A. Eisenhauer New guidelines to evaluate the response to treatment in solid tumors European Organization for Research and Treatment of Cancer, National Cancer Institute of the United States, National Cancer Institute of Canada J Natl Cancer Inst 92 2000 205 206
21. M.M. Oken, R.H. Creech, D.C. Tormey Toxicity and response criteria of the Eastern Cooperative Oncology Group Am J Clin Oncol 5 1982 649 655 (Pubitemid 13149996)
22. ICH Efficacy Guidelines E6(R1) Good Clinical Practice: Consolidated Guideline http://www.ich.org/fileadmin/Public-Web-Site/ICH-Products/Guidelines/ Efficacy/E6-R1/Step4/E6-R1-Guideline.pdf
23. N.P. vanErp, H. Gelderblom, H.J. Guchelaar Clinical pharmacokinetics of tyrosine kinase inhibitors Cancer Treat Rev 35 2009 692 706
24. Cancer Therapy Evaluation Program Common toxicity criteria Version 2.0. DCTD, NCI, NIH, DHHS http://ctep.cancer.gov/protocolDevelopment/electronic- applications/docs/ctcv2nom-4-30-99-final3.pdf 1998
25. D. Collet Modelling Survival Data in Medical Research 3rd ed. 1994 Blackwell Scientific Oxford
26. A.G. Pallis, A. Voutsina, A. Kalikaki 'Classical' but not 'other' mutations of EGFR kinase domain are associated with clinical outcome in gefitinib-treated patients with non-small cell lung cancer Br J Cancer 97 2007 1560 1566 (Pubitemid 350175853)
27. M.G. Kris, R.B. Natale, R.S. Herbst Efficacy of gefitinib, an inhibitor of the epidermal growth factor receptor tyrosine kinase, in symptomatic patients with non-small cell lung cancer: a randomized trial JAMA 290 2003 2149 2158 (Pubitemid 37432975)
28. W. Pao, J. Chmielecki Rational, biologically based treatment of EGFR-mutant nonsmall-cell lung cancer Nat Rev Cancer 10 2010 760 774
29. T.S. Mok, Y.L. Wu, S. Thongprasert Gefitinib or carboplatin-paclitaxel in pulmonary adenocarcinoma N Engl J Med 361 2009 947 957
30. M. Fukuoka, Y. Wu, S. Thongprasert Biomarker analyses from a phase III, randomized, open-label, first-line study of gefitinib (G) versus carboplatin/paclitaxel (C/P) in clinically selected patients (pts) with advanced non-small cell lung cancer (NSCLC) in Asia (IPASS) J Clin Oncol 27 suppl 2009 abstract 8006 http://www.asco.org Accessed: September 6, 2011
31. M. Maemondo, A. Inoue, K. Kobayashi Gefitinib or chemotherapy for nonsmall-cell lung cancer with mutated EGFR N Engl J Med 362 2010 2380 2388
32. T. Mitsudomi, S. Morita, Y. Yatabe Gefitinib versus cisplatin plus docetaxel in patients with nonsmall-cell lung cancer harbouring mutations of the epidermal growth factor receptor (WJTOG3405): an open label, randomised phase 3 trial Lancet Oncol 11 2010 121 128
33. C. Zhou, Y.L. Wu, G. Chen Efficacy results from the randomised phase III optimal (CTONG 0802) study comparing first-line erlotinib versus carboplatin (CBDCA) plus gemcitabine (GEM), in Chinese advanced nonsmall-cell lung cancer (NSCLC) patients (pts) with EGFR activating mutations Ann Oncol 21 2010 abstract LBA 13
34. R. Rosell, R. Gervais, A. Vergnenegre Erlotinib versus chemotherapy (CT) in advanced non-small cell lung cancer (NSCLC) patients (p) with epidermal growth factor receptor (EGFR) mutations: interim results of the European Erlotinib Versus Chemotherapy (EURTAC) phase III randomized trial J Clin Oncol 29 suppl 2011 abstract 7503
35. L.V. Sequist, R.G. Martins, D. Spigel First-line gefitinib in patients with advanced nonsmall-cell lung cancer harboring somatic EGFR mutations J Clin Oncol 26 2008 2442 2449
36. A. De Luca, N. Normanno Predictive biomarkers to tyrosine kinase inhibitors for the epidermal growth factor receptor in nonsmall-cell lung cancer Curr Drug Targets 11 2010 851 864
37. A. Kalikaki, A. Koutsopoulos, M. Trypaki Comparison of EGFR and K-RAS gene status between primary tumours and corresponding metastases in NSCLC Br J Cancer 99 2008 923 929
38. K. Tsujino, T. Kawaguchi, A. Kubo Response rate is associated with prolonged survival in patients with advanced non-small cell lung cancer treated with gefitinib or erlotinib J Thorac Oncol 4 2009 994 1001
39. H. Linardou, I.J. Dahabreh, D. Kanaloupiti Assessment of somatic k-RAS mutations as a mechanism associated with resistance to EGFR-targeted agents: a systematic review and meta-analysis of studies in advanced nonsmall-cell lung cancer and metastatic colorectal cancer Lancet Oncol 9 2008 962 972
40. P.J. Roberts, T.E. Stinchcombe, C.J. Der Personalized medicine in nonsmall-cell lung cancer: is KRAS a useful marker in selecting patients for epidermal growth factor receptor-targeted therapy? J Clin Oncol 28 2010 4769 4777
41. R. Govindan INTERESTing biomarker to select IDEAL patients for epidermal growth factor receptor tyrosine kinase inhibitors: yes, for EGFR mutation analysis, others, I PASS J Clin Oncol 28 2010 713 715
42. F.A. Shepherd, M.S. Tsao Epidermal growth factor receptor biomarkers in nonsmall-cell lung cancer: a riddle, wrapped in a mystery, inside an enigma J Clin Oncol 28 2010 903 905